Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Radiation Therapy
  •  Gynecological Cancers
  •  Lymphoma
  •  Brain and Spinal Cord Cancer
  •  Chemotherapy and Radiotherapy
  •  Head and Neck Oncology
  •  Gastrointestinal Cancer
  •  Urological Cancers

Abstract

Citation: Clin Oncol. 2016;1(1):1050.DOI: 10.25107/2474-1663.1050

A Case of High Grade Advanced Neuroendocrine Cancer of the Bladder Treated with Bevacizumab, Cisplatin, Etoposide and Cyclophosphamide-Based Chemotherapy

Sroussi M, Fournier L, Blons H and Oudard S

Department of Oncology, European Georges Pompidou Hospital, René Descartes University, France
Department of Radiology, European Georges Pompidou Hospital, René Descartes University, France
Department of Biochemistry, European Georges Pompidou Hospital, René Descartes University, France

*Correspondance to: St�phane Oudard 

 PDF  Full Text Case Report | Open Access

Abstract:

Neuroendocrine bladder cancer accounts for <1% of all bladder cancers. There is no standard treatment for neuroendocrine bladder cancer; instead therapy is mainly based on agents used in small cell lung cancer. The case report details a patient with neuroendocrine bladder cancer who had disease progression after conventional chemotherapy based on etoposide and cisplatin. During second-line chemotherapy with etoposide, cisplatin and ifosfamide the patient experienced a high-grade neurological adverse event, without any decrease in tumor burden. Third-line chemotherapy with cisplatin, cyclophosphamide, etoposide and bevacizumab was associated with an almost complete response but the patient died of hematological toxicity. The good response to the combination of cisplatin, cyclophosphamide, etoposide and bevacizumab suggests that antiangiogenic therapies may be a treatment option for neuroendocrine bladder cancer that deserved further study.

Keywords:

Small cell bladder cancer; Bevacizumab; Cisplatin; Etoposide; Cyclophosphamide; Hematotoxicity

Cite the Article:

Sroussi M, Fournier L, Blons H, Oudard S. A Case of High Grade Advanced Neuroendocrine Cancer of the Bladder Treated with Bevacizumab, Cisplatin, Etoposide and CyclophosphamideBased Chemotherapy. Clin Oncol. 2016; 1: 1050.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Serum Vitamin D Levels in Diabetes Mellitus Patients with Pulmonary Tuberculosis
 Abstract  PDF  Full Text
Dysregulated Circadian Clock and Aged Stem Cell: An Inflammatory Crosstalk?
 PDF  Full Text
View More...